	US 12,221,485 B2
	TMEM219 antibodies and therapeutic uses thereof
Paolo Fiorina, Boston, MA (US); Giovanni Amabile, Milan (IT); and Francesca D'Addio, Milan (IT)
Assigned to ENTHERA S.R.L., Milan (IT)
Filed by ENTHERA S.R.L., Milan (IT)
Filed on Jul. 12, 2024, as Appl. No. 18/772,062.
Application 18/772,062 is a continuation of application No. 17/777,021, previously published as PCT/EP2020/082292, filed on Nov. 16, 2020.
Claims priority of application No. 19209521 (EP), filed on Nov. 15, 2019; and application No. 20167459 (EP), filed on Apr. 1, 2020.
Prior Publication US 2024/0368290 A1, Nov. 7, 2024
Int. Cl. C07K 16/28 (2006.01); A61P 3/10 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 3/10 (2018.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

22 Claims

1. An antibody or antigen-binding fragment thereof comprising three heavy chain variable region (VH) CDRs and three light chain variable region (VL) CDRs, wherein

(a) the three VH CDRs respectively have the sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and the three VL CDRs respectively have the sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19; or

(b) the three VH CDRs respectively have the sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and the three VL CDRs respectively have the sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:166,

wherein the antibody or antigen-binding fragment thereof is capable of binding to transmembrane protein 219 (TMEM219).